| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 28,704.5 | 24,617.13 | 23,366.55 | 24,557.95 | 22,737.95 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 28,704.5 | 24,617.13 | 23,366.55 | 24,557.95 | 22,737.95 |
Other Operating Income | 297.37 | 238.25 | 88.94 | 216.68 | 360.55 |
Other Income | 557.38 | 290.59 | 320.35 | 3,195.42 | 86.2 |
Total Income | 29,559.25 | 25,145.97 | 23,775.84 | 27,970.05 | 23,184.7 |
Total Expenditure | 23,367.89 | 21,148.41 | 19,227.94 | 19,496.58 | 18,315.2 |
PBIDT | 6,191.36 | 3,997.56 | 4,547.9 | 8,473.47 | 4,869.5 |
Interest | 289.71 | 140.48 | 48.64 | 74.49 | 159.77 |
PBDT | 5,901.65 | 3,857.08 | 4,499.26 | 8,398.98 | 4,709.73 |
Depreciation | 1,521.66 | 1,244.58 | 1,126.52 | 1,055.38 | 966.71 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 1,777.54 | 1,071.48 | 662.82 | 2,321.82 | 956.95 |
Deferred Tax | -566.52 | -386.63 | 62.81 | -312.05 | -43.44 |
Reported Profit After Tax | 3,168.97 | 1,927.65 | 2,647.11 | 5,333.83 | 2,829.51 |
Minority Interest After NP | -4 | 0.15 | -1.04 | -1.02 | -1.46 |
Net Profit after Minority Interest | 3,172.97 | 1,927.5 | 2,648.15 | 5,334.85 | 2,830.97 |
Extra-ordinary Items | -114 | 0 | -100.44 | 1,924.7 | -19.45 |
Adjusted Profit After Extra-ordinary item | 3,286.97 | 1,927.5 | 2,748.59 | 3,410.15 | 2,850.42 |
EPS (Unit Curr.) | 54.16 | 32.9 | 45.19 | 91.04 | 48.32 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 450 | 300 | 900 | 400 | 300 |
Equity | 58.59 | 58.59 | 58.59 | 58.59 | 58.59 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 21.56 | 16.23 | 19.46 | 34.5 | 21.41 |
PBDTM(%) | 20.56 | 15.66 | 19.25 | 34.2 | 20.71 |
PATM(%) | 11.03 | 7.83 | 11.32 | 21.71 | 12.44 |
Aurobindo Pharma is going to launch Dasatinib in Q1 FY26, which will be in line with its plans to enhance its oncology portfolio in the US generics market.
Following the audit, the US FDA issued a Form 483 with 11 observations at closure, which Aurobindo Pharma described as small procedural observations.
Here are some of the stocks that may see significant price movement today: GAIL, Zydus Lifesciences, Aurobindo Pharma, etc.
As per the company, the drug functions by blocking a protein called RANKL, which is responsible for breaking down bone tissue.
Here are some of the stocks that may see significant price movement today: BHEL, Coromandel International, Aurobindo Pharma, etc.
As per the company’s filing with the bourses, the inspection was concluded with five procedural observations.
Revenue increased by 8.5% YoY to ₹7,978.5 crore.
The USFDA inspected the Unit 2 API manufacturing facility of Apitoria Pharma during September 23 to September 27, 2024
This is a medicine used to treat specific kinds of cancer. It can be administered only via an infusion.
Here are some of the stocks that may see significant price movement today: Vedanta, NHPC, Reliance Industries, etc.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
